甘精胰岛素与诺和灵N治疗2型糖尿病有效性研究.docVIP

甘精胰岛素与诺和灵N治疗2型糖尿病有效性研究 　　[摘要] 目的 探讨2型糖尿病治疗中甘精胰岛素与诺和灵N应用的有效性。 方法 将50例2型糖尿病患者分为甘精胰岛素组（25例）和诺和灵N组（25例），甘精胰岛素组患者每天服用甘精胰岛素，初始计量为0.20 U/kg；诺和灵N组患者每天服用诺和灵N，初始计量为0.10～0.15 U/kg。均在临睡前给予其皮下注射1次，每天1次。与此同时，在餐前15 min内，让两组患者口服初始计量为0.5 mg的胰岛素促泌剂瑞格列奈，每天3次。两组患者均治疗3个月为1个疗程。治疗前及治疗3个月后检测患者的空腹血糖（FPG）、餐后血糖（PPG）、糖化血红蛋白（HbA1c）、血脂、肝肾功能等，并对其身高、体重、腰臀围进行测量，将治疗过程中患者出现的低血糖情况详细记录下来。 结果 两组患者治疗后的FPG、PPG、HbA1c均明显低于治疗前，治疗前后两组患者的FPG、PPG、HbA1c相比差异均有统计学意义（P 　　[关键词] 2???糖尿病；甘精胰岛素；诺和灵N；有效性 　　[中图分类号] R587 [文献标识码] A [文章编号] 1673-7210（2013）11（c）-0090-04 　　Effectiveness of Glargine Insulin and Novolin N in the treatment of type 2 diabetes 　　LI Hongmei1 LI Jianbo2 　　1.Department of Endocrinology， Guangzhou General Hospital of Guangzhou Military Region， Guangdong Province， Guangzhou 510010， China； 2.Nanjing Medical University， Jiangsu Province， Nanjing 210029， China 　　[Abstract] Objective To investigate the effectiveness of Glargine Insulin and Novolin N in the treatment of type 2 diabetes. Methods 50 cases of patients with type 2 diabetes were divided into two groups， Glargine Insulin group （25 cases） and Novolin N group （25 cases）， the patients in Glargine Insulin group were given Glargine Insulin daily， the initial measurement was 0.20 U/kg； the patients in the Novolin N group were given Novolin N daily， the initially measurement was 0.10-0.15 U/kg. They were injected subcutaneously at bedtime give it once a day. At the same time， within 15 minutes before a meal， so that the two groups were initially measured as 0.5 mg of oral insulin secretagogues Repaglinide， 3 times a day. Two groups of patients were treated for three months as a course of treatment. Before treatment and 3 months after the detection， the fasting plasma glucose （FPG）， postprandial blood glucose （PPG）， glycosylated hemoglobin （HbA1c）， blood lipids， liver and kidney function， and their height， weight， waist and hip measurements occur during the treatment of hypoglycemia in patients with the situation were recorded in detail. Results A